Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Matthew R Quigley
With
DUSA Pharmaceuticals, Inc.
Patients with primary neoplastic brain tumors (Grades II-IV) will participate in this trial. Each patient will have been evaluated and found to have such a tumor by history and recent imaging studies (MRI) and deemed a surgical candidate based on current neurosurgical standards of care.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Suspected primary brain tumor
18 years of age or more
Normal marrow and organ function
Eastern Cooperative Group performance status ≤ 2
Women of childbearing potential must use adequate birth control
Ability to understand and willingness to sign a written informed consent form
Life expectancy not a consideration
You may not be if
Receiving any other investigational agents
History of allergic reactions to ALA
Personal or family history of porphyrias
Liver disease in the past year
Uncontrolled intercurrent illness
Pregnant or lactating women
Inability to undergo MRI with contrast
Clareo Health | Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
